As expected, in advanced breast cancers we observed a relatively high level of TP53 mutations (27%) in concordance with our previously published data in luminal A (17%) and luminal B (41%) BC [32] or globally in luminal BC (26%) [33]. The gene discussed is TP53; the disease is breast carcinoma.